Roger Harrison to Prodrugs
This is a "connection" page, showing publications Roger Harrison has written about Prodrugs.
Connection Strength
4.350
-
Annexin A5 as a targeting agent for cancer treatment. Cancer Lett. 2022 10 28; 547:215857.
Score: 0.809
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.598
-
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.
Score: 0.564
-
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 2015 Aug; 44(6):945-52.
Score: 0.498
-
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. J Biomed Sci. 2014 Jul 22; 21:65.
Score: 0.464
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
Score: 0.439
-
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011 Aug 01; 307(1):53-61.
Score: 0.371
-
Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011 Feb 28; 301(2):177-84.
Score: 0.362
-
Annexin-directed ß-glucuronidase for the targeted treatment of solid tumors. Protein Eng Des Sel. 2017 Feb; 30(2):85-94.
Score: 0.137
-
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest. 2013 Oct; 31(8):505-10.
Score: 0.110